Patents by Inventor Stephen Colin PRICE
Stephen Colin PRICE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10822342Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: February 1, 2019Date of Patent: November 3, 2020Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Patent number: 10323045Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: June 18, 2019Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, John Gary Montana, Stephen Colin Price
-
Publication number: 20190169198Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: February 1, 2019Publication date: June 6, 2019Inventors: George HYND, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Patent number: 10221180Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: March 5, 2019Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Calum Macleod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price
-
Publication number: 20180298032Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: October 18, 2018Inventors: George HYND, Patrizia TISSELLI, Calum MACLEOD, Samuel Edward MANN, John Gary MONTANA, Stephen Colin PRICE
-
Patent number: 10005776Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: June 26, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Stephen Colin Price, John Gary Montana
-
Patent number: 10005773Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: September 25, 2014Date of Patent: June 26, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, David Edward Clark, Janusz Jozef Kulagowski, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, Stephen Colin Price, John Gary Montana
-
Patent number: 9981962Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: October 22, 2015Date of Patent: May 29, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, John Gary Montana, Stephen Colin Price, Fabien Jean Ghislain Roussel
-
Patent number: 9981963Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: GrantFiled: September 25, 2014Date of Patent: May 29, 2018Assignee: Janssen Pharmaceutica NVInventors: George Hynd, Patrizia Tisselli, David Edward Clark, Janusz Jozef Kulagowski, Calum MacLeod, Samuel Edward Mann, Fabien Jean Ghislain Roussel, Stephen Colin Price, John Gary Montana
-
Publication number: 20170334906Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: November 23, 2017Inventors: George HYND, Patrizia TISSELLI, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Sameul Edward MANN, Stephen Colin PRICE, John Gray MONTANA
-
Publication number: 20170334915Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: November 23, 2017Inventors: George HYND, Patrizia TISSELLI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, John Gray MONTANA, Stephen Colin PRICE
-
Publication number: 20170334900Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: October 22, 2015Publication date: November 23, 2017Inventors: George HYND, Patrizia TISSELLI, Janusz Josef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, John Gary MONTANA, Stephen Colin PRICE, Fabien Jean Ghislain ROUSSEL
-
Publication number: 20160257679Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: September 25, 2014Publication date: September 8, 2016Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Terry Aaron PANCHAL, Stephen Colin PRICE, John Gary MONTANA
-
Publication number: 20160229851Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.Type: ApplicationFiled: September 25, 2014Publication date: August 11, 2016Inventors: George HYND, Patrizia TISSELLI, David Edward CLARK, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Fabien Jean Ghislain ROUSSEL, Stephen Colin PRICE, John Gary MONTANA
